Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study Evaluating the Feasibility, Safety, and Efficacy of the Neuro RX Gamma (Version 2) for the Treatment of Mild Cognitive Impairment (MCI)

NCT06618807 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT06618807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06618807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study Evaluating the Feasibility, Safety, and Efficacy of the Neuro RX Gamma (Version 2) for the Treatment of Mild Cognitive Impairment (MCI)
Lead sponsor
Unity Health Toronto
Phase
Not applicable
Overall status
Recruiting
Start date
January 10, 2025
Completion date
March 1, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment (mci) due to alzheimer's disease